Cargando…

T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model

Intralesional (IL) injection of Rose Bengal (PV-10) induces regression of injected and uninjected lesions in several murine tumor models. In this study, we investigated the anti-tumor response of combining IL PV-10 with blockade of the PD-1 / PD-L1 pathway and the role of immune cell populations in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Hao, Weber, Amy, Morse, Jennifer, Kodumudi, Krithika, Scott, Ellen, Mullinax, John, Sarnaik, Amod A., Pilon-Thomas, Shari
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918896/ https://www.ncbi.nlm.nih.gov/pubmed/29694419 http://dx.doi.org/10.1371/journal.pone.0196033

Ejemplares similares

Efficacy of intralesional injection with PV-10 in combination with co-inhibitory blockade in a murine model of melanoma
por: Pilon-Thomas, Shari, et al.
Publicado: (2014)

Intralesional Injection of Rose Bengal Induces a Systemic Tumor-Specific Immune Response in Murine Models of Melanoma and Breast Cancer
por: Toomey, Paul, et al.
Publicado: (2013)

Intralesional Rose Bengal in melanoma elicits tumor immunity via HMGB1
por: Liu, Hao, et al.
Publicado: (2015)

Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy
por: Kodumudi, Krithika N., et al.
Publicado: (2016)

Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1
por: Liu, Hao, et al.
Publicado: (2016)

Intralesional injection of rose bengal augments the efficacy of gemcitabine chemotherapy against pancreatic tumors
por: Innamarato, Patrick, et al.
Publicado: (2021)

Clinical results of combined vemurafenib and tumor-infiltrating lymphocyte therapy for metastatic melanoma
por: Sarnaik, Amod, et al.
Publicado: (2015)

Immediate triggering of 4-1BB co-stimulation during initiation of tumor-infiltrating lymphocyte (TIL) expansion from melanoma tumors accelerates CD8+ T-cell outgrowth and tumor specificity
por: Chacon, Jessica, et al.
Publicado: (2013)

Expansion and characterization of tumor-infiltrating lymphocytes from human sarcoma
por: Hall, MacLean, et al.
Publicado: (2015)

PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2020)

High response rate to PD-1 blockade in desmoplastic melanomas
por: Eroglu, Zeynep, et al.
Publicado: (2018)

Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion
por: Alvarez, Maite, et al.
Publicado: (2020)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma
por: Thompson, John F., et al.
Publicado: (2014)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Continuous 4–1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy
por: Chacon, Jessica Ann, et al.
Publicado: (2013)

Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8(+) Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy
por: Chacon, Jessica Ann, et al.
Publicado: (2013)

PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV
por: Davar, Diwakar, et al.
Publicado: (2015)

Identification ACTA2 and KDR as key proteins for prognosis of PD‐1/PD‐L1 blockade therapy in melanoma
por: Wang, Yuchen, et al.
Publicado: (2021)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models
por: Chen, Chun-Yu, et al.
Publicado: (2017)

Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade
por: Bochem, Jonas, et al.
Publicado: (2019)

Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma
por: Frias, Alex, et al.
Publicado: (2023)

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
por: Bertrand, Florie, et al.
Publicado: (2017)

Fecal microbiota transplantation: can it circumvent resistance to PD-1 blockade in melanoma?
por: Derosa, Lisa, et al.
Publicado: (2021)

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
por: Hamanishi, Junzo, et al.
Publicado: (2016)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
por: Chen, Chun-Yu, et al.
Publicado: (2018)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
por: Chen, Qi, et al.
Publicado: (2018)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
por: Zhao, Bin, et al.
Publicado: (2020)

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
por: Katsuya, Hiroo, et al.
Publicado: (2023)

Selinexor, a selective inhibitor of nuclear export (SINE), shows enhanced activity in combination with PD-1/PD-L1 blockade in syngeneic murine models of colon cancer and melanoma
por: Farren, Matthew R, et al.
Publicado: (2015)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea, Miruna, et al.
Publicado: (2021)

CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma
por: Hu, Zhang-Wei, et al.
Publicado: (2022)

Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma
por: Kos, Spela, et al.
Publicado: (2019)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kubogv2rtv35fhoct1k402sb20